{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:10:02Z","timestamp":1792807802245,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The assessment of metastatic breast cancer (MBC) can be limited with routine imaging such as computed tomography (CT) especially in bone-only or bone-predominant disease. This analysis investigates the effects of the use of WBMRI in addition to the use of routine CT, bone scintigraphy (BS) and fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET\/CT) on influencing systemic anti-cancer treatment (SACT) decisions in patients with known MBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MBC patients undergoing SACT who had WBMRI undertaken within 8\u00a0weeks of either a routine CT, BS or FDG-PET\/CT were reviewed retrospectively. The clinical indications for undertaking the WBMRI examinations were recorded. Data on the extent and distribution of the disease were collected and discordance\/concordance of disease status across the imaging modalities were compared. SACT decisions at each time point were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 105 MBC patients with 148 WBMRI studies paired with CT, BS or FDG-PET\/CT. 50 pairs (33.8%) showed differences in the extent of disease, with 44 pairs due to additional sites (AS) reported on WBMRI alone.<\/jats:p>\n                    <jats:p>81 patients\u00a0(Group 1) had one WBMRI paired with routine imaging due to a variety of indications, with clinical symptoms (such as bone pain) being the most common (24.7%).<\/jats:p>\n                    <jats:p>24 patients (Group 2) had more than one WBMRI study paired with routine imaging comprising 67 pairs. 13\/67 pairs (19.4%) showed discordance in assessments. 10\/13 pairs had progressive disease (PD) reported on WBMRI alone.<\/jats:p>\n                    <jats:p>SACT change due to AS reported on WBMRI alone occurred in 21\/23 pairs (91.3%) in Group 1. SACT change due to PD reported on WBMRI alone in Group 2 occurred in 6\/14 pairs (42.9%). SACT change due to AS\/PD in both groups occurred in 11\/102 pairs (10.8%) with known invasive ductal carcinoma (IDC) and 13\/28 pairs (46.4%) with invasive lobular carcinoma (ILC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of WBMRI in MBC led to earlier recognition of PD and SACT change compared with the other imaging modalities. A higher proportion of discordant response assessments and SACT changes were observed in ILC compared with IDC in our patient group, although larger-scale studies are required to investigate this further.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-022-00464-4","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T05:03:22Z","timestamp":1654578202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-1846","authenticated-orcid":false,"given":"Basrull N.","family":"Bhaludin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanthi","family":"Senthivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil D.","family":"Soneji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Hujairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie E.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia F.","family":"Okines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair E.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow-Mu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"464_CR1","unstructured":"The Royal College of Radiologists. Guidance on screening and symptomatic breast imaging: Fourth edition. Clinical Radiology The Royal College of Radiologists [Internet]. The Royal College of Radiologists; 2019 [cited 2021 May 9]; Available from: www.rcr.ac.uk"},{"issue":"484","key":"464_CR2","first-page":"93","volume":"19","author":"WJ Gradishar","year":"2021","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN Guidelines\u00ae insights: breast cancer, Version 4.2021. J Natl Comprehens Cancer Netw. 2021;19(484):93.","journal-title":"J Natl Comprehens Cancer Netw"},{"key":"464_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer\u2606. Ann Oncol. 2021;32:1475\u201395.","journal-title":"Ann Oncol"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"issue":"6243s LP","key":"464_CR5","first-page":"6249s","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clin Cancer Res. 2006;12(6243s LP):6249s.","journal-title":"Clin Cancer Res"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s12149-017-1202-3","volume":"31","author":"T Sugihara","year":"2017","unstructured":"Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, et al. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Ann Nuclear Med Springer Japan. 2017;31:719\u201325.","journal-title":"Ann Nuclear Med Springer Japan"},{"issue":"651","key":"464_CR7","first-page":"7","volume":"102","author":"T Hamaoka","year":"2010","unstructured":"Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Bri J Cancer. 2010;102(651):7.","journal-title":"Bri J Cancer"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1200\/JCO.1995.13.5.1123","volume":"13","author":"CL Vogel","year":"1995","unstructured":"Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol United States. 1995;13:1123\u20138.","journal-title":"J Clin Oncol United States"},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","volume":"22","author":"J Rong","year":"2013","unstructured":"Rong J, Wang S, Ding Q, Yun M, Zheng Z, Ye S. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22:86\u201391.","journal-title":"Surg Oncol"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/RLU.0b013e31815f23b7","volume":"33","author":"P Shie","year":"2008","unstructured":"Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med United States. 2008;33:97\u2013101.","journal-title":"Clin Nucl Med United States"},{"key":"464_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/annonc\/mdq343","volume":"22","author":"A Constantinidou","year":"2011","unstructured":"Constantinidou A, Martin A, Sharma B, Johnston SRD. Positron emission tomography\/computed tomography in the management of recurrent\/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011;22:307\u201314.","journal-title":"Ann Oncol"},{"key":"464_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/annonc\/mdu558","volume":"26","author":"DK Woolf","year":"2015","unstructured":"Woolf DK, Padhani AR, Makris A. Assessing response to treatment of bone metastases from breast cancer: What should be the standard of care? Ann Oncol. 2015;26:1048\u201357.","journal-title":"Ann Oncol"},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.breast.2013.03.006","volume":"22","author":"NU Lin","year":"2013","unstructured":"Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22:203\u201310.","journal-title":"Breast"},{"issue":"1666","key":"464_CR14","first-page":"73","volume":"42","author":"BZ Dashevsky","year":"2015","unstructured":"Dashevsky BZ, Goldman DA, Parsons M, G\u00f6nen M, Corben AD, Jochelson MS, et al. Appearance of untreated bone metastases from breast cancer on FDG PET\/CT: importance of histologic subtype. Eur J Nucl Med Mole Imaging. 2015;42(1666):73.","journal-title":"Eur J Nucl Med Mole Imaging"},{"key":"464_CR15","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","volume":"56","author":"MP Hogan","year":"2015","unstructured":"Hogan MP, Goldman DA, Dashevsky B, Riedl CC, G\u00f6nen M, Osborne JR, et al. Comparison of 18F-FDG PET\/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nucl Med. 2015;56:1674\u201380.","journal-title":"J Nucl Med"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/jmri.24548","volume":"39","author":"AR Padhani","year":"2014","unstructured":"Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, De Bono JS. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging. 2014;39:1049\u201378.","journal-title":"J Magn Reson Imaging"},{"key":"464_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bjh.14827","volume":"178","author":"A Chantry","year":"2017","unstructured":"Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, et al. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol. 2017;178:380\u201393.","journal-title":"Br J Haematol"},{"key":"464_CR18","first-page":"5","volume":"291","author":"C Messiou","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiol Radiol Soc North Am. 2019;291:5\u201313.","journal-title":"Radiol Radiol Soc North Am"},{"key":"464_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, et al. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol Eur Assoc Urol. 2017;71:81\u201392.","journal-title":"Eur Urol Eur Assoc Urol"},{"key":"464_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2017.03.001","volume":"77","author":"M Kosmin","year":"2017","unstructured":"Kosmin M, Makris A, Joshi PV, Ah-See ML, Woolf D, Padhani AR. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer. 2017;77:109\u201316.","journal-title":"Eur J Cancer"},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0205251","volume":"13","author":"F Zugni","year":"2018","unstructured":"Zugni F, Ruju F, Pricolo P, Alessi S, Iorfida M, Colleoni MA, et al. The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer. PLoS ONE. 2018;13:1\u201316.","journal-title":"PLoS ONE"},{"key":"464_CR22","first-page":"622","volume":"297","author":"M Kosmin","year":"2020","unstructured":"Kosmin M, Padhani AR, Gogbashian A, Woolf D, Ah-See M-L, Ostler P, et al. Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiol United States. 2020;297:622\u20139.","journal-title":"Radiol United States"},{"issue":"1364","key":"464_CR23","first-page":"82","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(1364):82.","journal-title":"Arch Pathol Lab Med"},{"key":"464_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mole Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mole Imaging"},{"key":"464_CR25","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1007\/s00330-011-2221-4","volume":"21","author":"HL Yang","year":"2011","unstructured":"Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT MRI bone scintigraphy. Eur Radiol. 2011;21:2604\u201317.","journal-title":"Eur Radiol"},{"key":"464_CR26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2214\/AJR.13.11156","volume":"202","author":"H He","year":"2014","unstructured":"He H, Gonzalez A, Robinson E, Yang WT. Distant metastatic disease manifestations in infiltrating lobular carcinoma of the breast. Am J Roentgenol. 2014;202:1140\u20138.","journal-title":"Am J Roentgenol"},{"key":"464_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2214\/ajr.175.3.1750795","volume":"175","author":"CB Winston","year":"2000","unstructured":"Winston CB, Hadar O, Teitcher JB, Caravelli JF, Sklarin NT, Panicek DM, et al. Metastatic lobular carcinoma of the breast: Patterns of spread in the chest, abdomen, and pelvis on CT. Am J Roentgenol. 2000;175:795\u2013800.","journal-title":"Am J Roentgenol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00464-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-022-00464-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00464-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T17:09:35Z","timestamp":1654621775000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-022-00464-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1186\/s40644-022-00464-4","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Committee for Clinical Research of the Royal Marsden Hospital (Reference: SE1070).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Our research contains no personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}